A Phase I/II Study of the ALK Inhibitor CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer

Trial Profile

A Phase I/II Study of the ALK Inhibitor CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Alectinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 21 Feb 2017 Results published in a Roche media release.
    • 21 Feb 2017 According to a Roche media release, the European Commission has granted a conditional marketing authorisation for Alecensa (alectinib) as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. The approval was based on data from this and another trial (NP28673).
    • 16 Dec 2016 According to a Roche media release, the Committee for Medicinal Products for Human Use (CHMP) of EMA has adopted a positive opinion for the use of Alecensa (alectinib) for the treatment of adult patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with crizotinib. The opinion was based on data from this and another trial (NP28673).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top